Amphista earns milestone via Merck alliance

Amphista is a leader in the discovery of next-generation, Targeted Protein Degradation (TPD) medicines. The target that has triggered the payment also remains under wraps.

Under the agreement, Amphista is responsible for the discovery and early development of small molecule protein degraders using its Eclipsys® platform. Merck is granted a global exclusive licence to the resulting degrader molecules and is responsible for further development and commercialisation.

Antony Mattessich, Chief Executive Officer at Amphista, said: “As we continue to build our portfolio of first- and/or best-in-class Targeted Glues™, we are delighted to have reached an important milestone in our collaboration with Merck. 

“The progress we have made together speaks to the effective partnership between scientists from both companies, enabling us to focus on advancing high-quality compounds for further development. 

“This achievement reinforces the exceptional capabilities of our Eclipsys® platform in the rational design of orally bioavailable protein degraders, bringing us a step closer to improving patient outcomes.”